H.Q. Guo

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

A. Zhou, T. Sun, X.Q. Yan, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.